Lung Cancer

Next-generation sequencing (NGS) in metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million.

The FDA has granted breakthrough therapy designation to the kinase inhibitor crizotinib (Xalkori) for two indications.

CE lesson worth 1 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.

The FDA has granted a priority review to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the frontline treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

Helena A. Yu, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explains the implications of the approval of osimertinib as the frontline standard of care for patients with EGFR-mutant non–small cell lung cancer.

The FDA has granted a priority review for frontline use of the PD-1 inhibitor pembrolizumab (Keytruda) in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.

The FDA has approved osimertinib (Tagrisso) for frontline use in patients with non–small cell lung cancer (NSCLC) who have EGFR-mutated tumors.

The FDA has granted priority review to a supplemental biologics license application for nivolumab (Opdivo) to be used to treat patients with small cell lung cancer who have already had two or more lines of therapy, and whose disease has continued to progress.

Significant improvements over chemotherapy alone makes frontline pembrolizumab (Keytruda) treatment a clear choice.

The American Society for Radiation Oncology released an updated guideline which states that some patients with incurable non-small cell lung cancer should receive concurrent chemotherapy along with palliative thoracic radiation therapy.

The surgical landscape for non-small cell lung cancer is shifting now that durvalumab (Imfinzi), the first immunotherapy for stage III NSCLC, has been approved for the FDA.

The Pivot Nurse in Oncology (PNO) role appears to make a substantial difference in care for patients being treated for advanced lung cancer, according to a study presented at the European Lung Cancer Congress (ELCC) 2018.

The FDA has granted a priority review designation to dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).

Therapeutic strategies for treating less-common molecular targets found in non–small cell lung cancer (NSCLC), such as ROS1, NTRK, MET, and HER2, are under development.

The FDA has approved a supplemental biologics license application to add a 4-week dosing schedule for nivolumab (Opdivo) across several of the PD-1 inhibitor’s indications.

As part of a multidisciplinary team, nurses often reference guidelines to assist in treatment decisions for patients with cancer. Now, they also have guidance on how to treat individuals that comprise an underserved population of patients: those living with HIV and cancer.

Smoking prevention programs need to include warnings that the risk of “trying” a cigarette can lead to daily smoking, and that 69% of people in global survey data who have tried a cigarette became smokers.

The FDA has approved durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Pfizer announced that the FDA has granted a priority review to a new drug application for lorlatinib, an ALK inhibitor, for use in patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

Patients whose cancers have metastasized to the brain or central nervous system are often excluded from clinical trials, but now, new guidelines may help researchers identify appropriate clinical trials in which these people may be included.

Some underprivileged and minority groups are underrepresented in lung cancer clinical trials, which can affect how and whether they receive appropriate care.

Approval opens up treatment possibilities for lung cancer patients with rare genetic mutations.

Cisplatin, a platinum-based chemotherapy agent that is used to treat testicular cancer, non-small cell lung cancer, bladder cancer, cervical cancer, ovarian cancer and head and neck cancer, has been found to cause a significant amount of hearing loss in patients, according to a recent article published in Nature Communications.

The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of osimertinib as a first-line treatment for patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.